ConductScience.org, home

Comparison · NCT01004029-2e0c38c7

Hydroxyprogesterone Caproate Injection, 250 mg/mL vs Vehicle: Stillbirths

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hydroxyprogesterone Caproate Injection, 250 mg/mL vs Vehicle: Stillbirths. Trial comparisons, record NCT01004029-2e0c38c7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01004029-2e0c38c7

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0110.006290.0191wilson
Risk in group 20.005370.001830.0157wilson
Risk difference, group 1 minus group 20.00561-0.00570.0145newcombe hybrid score
Risk ratio, group 1 over group 22.050.587.22log
Odds ratio, group 1 over group 22.060.5787.32log
Number needed to treat, for one more participant with the outcome on Hydroxyprogesterone Caproate Injection, 250 mg/mL than on Vehicle178from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Hydroxyprogesterone Caproate Injection, 250 mg/mLHPC 250 mg/mL in oil~Hydroxyprogesterone Caproate Injection, 250mg/mL: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.121,093OG001
Group 2VehicleCastor Oil~Vehicle: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.3559OG000

Outcome

Type
SECONDARY
Title
Stillbirths
Description
Defined as all stillbirths/fetal deaths/in utero fetal losses occurring from 20 weeks gestation until term.
Time frame
20 weeks gestation until term
Population

Source ClinicalTrials.gov

Trial

Title
Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
NCT number
NCT01004029
Phases
PHASE3
Conditions
Preterm Birth
Interventions
Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL, Vehicle
Lead sponsor
AMAG Pharmaceuticals, Inc.
Results first posted
2021-01-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01004029-2e0c38c7